Form 4: Vericel Corp Director Steven Gilman Reports Stock Transactions
SEC Form 4
Director Steven Gilman reports exercising stock options and selling shares of Vericel Corp under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 4, 2024, Steven Gilman, a director of Vericel Corp, executed transactions involving the company's common stock.
- Gilman exercised options to acquire 5,000 shares of common stock at a price of $3.74 per share.
- Simultaneously, Gilman sold 5,000 shares of common stock at a price of $48.58 per share.
- Following these transactions, Gilman directly owns 11,000 shares of Vericel Corp.
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There's no indication of positive or negative sentiment towards the company's prospects.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to stock sales.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge insider sentiment and potential future stock performance.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the financial industry.
- Comparing Gilman's transactions to those of other directors in similar biotech companies could provide insights into the relative valuation and prospects of Vericel Corp.
- For example, if other directors in comparable companies are also selling shares, it might indicate a broader trend of profit-taking or concerns about the industry outlook.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they provide insight into insider activity.
- The impact on employees, customers, suppliers, and creditors is likely to be negligible.
Key Dates
| Date | Description |
|---|---|
| March 20, 2015 | Date on which the stock options were granted. |
| May 1, 2015 | Final vesting date for the stock options. |
| May 30, 2024 | Date the Rule 10b5-1 trading plan was adopted. |
| September 4, 2024 | Date of the stock option exercise and share sale. |
| September 5, 2024 | Date of signature on the Form 4 filing. |
| March 20, 2025 | Original expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.